A case of statin-induced interstitial pneumonitis due to rosuvastatin

Tuberculosis and Respiratory Diseases

Volumn 78, Issue 3, 2015, Pages 281-285

  Kim, Se Yong ^a   Kim, Se Jin ^a   Yoon, Doran ^b   Hong, Seung Wook ^b   Park, Sehhoon ^b   Ock, Chan Young ^b  

^a Korean Armed Forces Medical Command   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Chemically induced disorders; Lung diseases, interstitial; Rosuvastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AMOXICILLIN PLUS CLAVULANIC ACID; ASPARTATE AMINOTRANSFERASE; BICARBONATE; BILIRUBIN; C REACTIVE PROTEIN; CARBON DIOXIDE; CHOLESTEROL; CILOSTAZOL; CREATININE; HEMOGLOBIN; LEVACECARNINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OXYGEN; PREDNISOLONE; PRESCRIPTION DRUG; PROTEIN; ROSUVASTATIN; STEROID;

ADULT; ALLERGIC PNEUMONITIS; ANTIBIOTIC THERAPY; ARTICLE; BASOPHIL; CARBON DIOXIDE TENSION; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIFFUSE CAPACITY FOR CARBON MONOXIDE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN TISSUE; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION; LUNG LAVAGE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTE; NEUTROPHIL COUNT; OXYGEN SATURATION; OXYGEN TENSION; PRESCRIPTION; RESPIRATORY TRACT PARAMETERS; STEROID THERAPY; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; TRANSIENT ISCHEMIC ATTACK; UREA NITROGEN BLOOD LEVEL;

EID: 84962751883     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2015.78.3.281     Document Type: Article

References (9)

1. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-50.
2. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109(23 Suppl 1):III50-7.
3. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005;111:3051-7.
4. Hill C, Zeitz C, Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust N Z J Med 1995;25:745-6.
5. Liebhaber MI, Wright RS, Gelberg HJ, Dyer Z, Kupperman JL. Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases. Chest 1999;115:886-9.
6. Veyrac G, Cellerin L, Jolliet P. A case of interstitial lung disease with atorvastatin (Tahor) and a review of the literature about these effects observed under statins. Therapie 2006;61:57-67.
7. Fernandez AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest 2008;134:824-30.
8. Huang LK, Tsai MJ, Tsai HC, Chao HS, Lin FC, Chang SC. Statin-induced lung injury: diagnostic clue and outcome. Postgrad Med J 2013;89:14-9.
9. Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res 2012;13:39.